» Articles » PMID: 25698172

Cerebrospinal Fluid Levels of Chitinase 3-like 1 and Neurofilament Light Chain Predict Multiple Sclerosis Development and Disability After Optic Neuritis

Overview
Journal Mult Scler
Publisher Sage Publications
Specialty Neurology
Date 2015 Feb 21
PMID 25698172
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cerebrospinal fluid (CSF) biomarkers have been suggested to predict multiple sclerosis (MS) after clinically isolated syndromes, but studies investigating long-term prognosis are needed.

Objective: To assess the predictive ability of CSF biomarkers with regard to MS development and long-term disability after optic neuritis (ON).

Methods: Eighty-six patients with ON as a first demyelinating event were included retrospectively. Magnetic resonance imaging (MRI), CSF leukocytes, immunoglobulin G index and oligoclonal bands were registered. CSF levels of chitinase-3-like-1, osteopontin, neurofilament light-chain, myelin basic protein, CCL2, CXCL10, CXCL13 and matrix metalloproteinase-9 were measured by enzyme-linked immunosorbent assay. Patients were followed up after 13.6 (range 9.6-19.4) years and 81.4% were examined, including Expanded Disability Status Scale and MS functional composite evaluation. 18.6% were interviewed by phone. Cox regression, multiple regression and Spearman correlation analyses were used.

Results: Forty-six (53.5%) developed clinically definite MS (CDMS) during follow-up. In a multivariate model MRI (p=0.0001), chitinase 3-like 1 (p=0.0033) and age (p=0.0194) combined predicted CDMS best. Neurofilament light-chain predicted long-term disability by the multiple sclerosis severity scale (p=0.0111) and nine-hole-peg-test (p=0.0202). Chitinase-3-like-1 predicted long-term cognitive impairment by the paced auditory serial addition test (p=0.0150).

Conclusion: Neurofilament light-chain and chitinase-3-like-1 were significant predictors of long-term physical and cognitive disability. Furthermore, chitinase-3-like-1 predicted CDMS development. Thus, these molecules hold promise as clinically valuable biomarkers after ON as a first demyelinating event.

Citing Articles

Fluid biomarkers in multiple sclerosis: from current to future applications.

Di Filippo M, Gaetani L, Centonze D, Hegen H, Kuhle J, Teunissen C Lancet Reg Health Eur. 2024; 44:101009.

PMID: 39444698 PMC: 11496979. DOI: 10.1016/j.lanepe.2024.101009.


Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its predictive ability of multiple sclerosis.

Passali M, Galea I, Knudsen M, Lau L, Cramer S, Frederiksen J J Neurol. 2024; 271(9):6127-6135.

PMID: 39052040 PMC: 11377639. DOI: 10.1007/s00415-024-12587-8.


Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis.

Chitnis T, Qureshi F, Gehman V, Becich M, Bove R, Cree B Nat Commun. 2024; 15(1):4297.

PMID: 38769309 PMC: 11106245. DOI: 10.1038/s41467-024-48602-9.


Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis.

Akesson J, Hojjati S, Hellberg S, Raffetseder J, Khademi M, Rynkowski R Nat Commun. 2023; 14(1):6903.

PMID: 37903821 PMC: 10616092. DOI: 10.1038/s41467-023-42682-9.


Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis.

Talaat F, Abdelatty S, Ragaie C, Dahshan A Neurol Sci. 2023; 44(9):3243-3252.

PMID: 36988727 PMC: 10415417. DOI: 10.1007/s10072-023-06764-2.